FDA-Approved Oligonucleotide Therapies in 2017
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2017/05/01
-
Journal
-
Indian UGC (journal)
-
Refrences61
-
Citations453
-
Cy A. Stein
-
Daniela Castanotto
Journal Categories
Medicine
Medicine (General)
Science
Biology (General)
Genetics
Technology
Chemical technology
Biotechnology
You May Also Like
- Plat-E: an efficient and stable system for transient packaging of retroviruses
- Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
- High Levels of Foreign Gene Expression in Hepatocytes after Tail Vein Injections of Naked Plasmid DNA
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy | Human Genetics |
| 47 | 2016 |
What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance | Blood Journal |
| 51 | 2016 |
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure | Blood Journal |
| 199 | 2016 |
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy | Annals of Neurology |
| 369 | 2016 |
| Sinusoidal obstruction syndrome | Clinics and Research in Hepatology and Gastroenterology |
| 70 | 2016 |
Refrences Analysis
The category
Science: Biology (General) 16
is the most frequently represented among the references in this article. It primarily includes studies from Biochemistry and Annals of Neurology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? | Cardiology and Therapy |
| 1 | 2024 |
| Engineered smart materials for RNA based molecular therapy to treat Glioblastoma | Bioactive Materials | 1 | 2024 | |
| siRNA as potential therapeutic strategy for hypertension | European Journal of Pharmacology |
| 2024 | |
| Role of regulatory non-coding RNAs in traumatic brain injury | Neurochemistry International |
| 1 | 2024 |
| The landscape of nanoparticle-based siRNA delivery and therapeutic development | Molecular Therapy |
| 3 | 2024 |
Citations Analysis
The category
Science: Biology (General) 146
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma and was published in 2017. The most recent citation comes from a 2024 study titled siRNA as potential therapeutic strategy for hypertension. This article reached its peak citation in 2020, with 102 citations. It has been cited in 265 different journals, 21% of which are open access. Among related journals, the Molecular Therapy - Nucleic Acids cited this research the most, with 16 citations. The chart below illustrates the annual citation trends for this article.